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Abstract
Background: The incidence of type one diabetes is increasing. A diagnosis of type one diabetes comes with
serious, lifelong implications including the need to inject exogenous insulin multiple times each day. Failure to
adhere to a strict treatment regime can lead to microvascular and macrovascular complications involving the
cardiovascular, vascular, renal and ocular systems. Current research is focused on the prevention of diabetes.
More specifically, recent research addresses how treatment can be offered to slow disease progression and
preserve pancreatic beta cell function. Can adjunctive treatment with vitamin D in patients with newly
diagnosed type one diabetes preserve pancreatic beta cell function?
Methods: An exhaustive search of medical literature was conducted using Medline-OVID, CINAHL, EBMR
Multifile, Web of Science and NIH clinical trials using the keywords: Vitamin D, type 1 diabetes mellitus, and
beta cell function. Relevant articles were assessed for quality using GRADE.
Results: Three studies met inclusion criteria and were included in this systematic review. A two-part,
randomized, double blind, placebo-controlled trial with 25 subjects showed supplementation with 1 alpha,
25-Dihydroxyvitamin D3 was safe, but showed no difference in stimulated C-peptide levels between
treatment patients and placebo. A randomized, double blind, placebo-controlled trial with 34 subjects showed
no difference in stimulated C-peptide levels between patients supplemented with calcitriol or placebo. Finally,
a randomized, double blind, placebo-controlled trial with 38 patients showed a higher level of residual C-
peptide production in patients treated with cholecalciferol versus placebo. This study also demonstrated
moderate evidence towards vitamin D supplementation and subsequent immune-protective benefits.
Conclusion: Overall, there isn’t compelling evidence to show that Vitamin D supplementation can preserve
pancreatic beta cell function in patients with newly diagnosed type one diabetes. However, it appears that
there is modest evidence to show that vitamin D, specifically in the form of cholecalciferol, has the ability to
slow the decline of residual beta cell function. Furthermore, it appears that supplementation with vitamin D is
safe and could provide immunity benefits that have yet to be proven.
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Abstract   
 
Background:  The incidence of type one diabetes is increasing. A diagnosis of type one 
diabetes comes with serious, lifelong implications including the need to inject exogenous 
insulin multiple times each day.  Failure to adhere to a strict treatment regime can lead to 
microvascular and macrovascular complications involving the cardiovascular, vascular, 
renal and ocular systems. Current research is focused on the prevention of diabetes. More 
specifically, recent research addresses how treatment can be offered to slow disease 
progression and preserve pancreatic beta cell function. Can adjunctive treatment with 
vitamin D in patients with newly diagnosed type one diabetes preserve pancreatic beta 
cell function? 
 
Methods:  An exhaustive search of medical literature was conducted using Medline-
OVID, CINAHL, EBMR Multifile, Web of Science and NIH clinical trials using the 
keywords: Vitamin D, type 1 diabetes mellitus, and beta cell function. Relevant articles 
were assessed for quality using GRADE.  
 
Results:  Three studies met inclusion criteria and were included in this systematic 
review. A two-part, randomized, double blind, placebo-controlled trial with 25 subjects 
showed supplementation with 1 alpha, 25-Dihydroxyvitamin D3 was safe, but showed no 
difference in stimulated C-peptide levels between treatment patients and placebo. A 
randomized, double blind, placebo-controlled trial with 34 subjects showed no difference 
in stimulated C-peptide levels between patients supplemented with calcitriol or placebo. 
Finally, a randomized, double blind, placebo-controlled trial with 38 patients showed a 
higher level of residual C-peptide production in patients treated with cholecalciferol 
versus placebo.  This study also demonstrated moderate evidence towards vitamin D 
supplementation and subsequent immune-protective benefits.   
 
Conclusion:  Overall, there isn’t compelling evidence to show that Vitamin D 
supplementation can preserve pancreatic beta cell function in patients with newly 
diagnosed type one diabetes. However, it appears that there is modest evidence to show 
that vitamin D, specifically in the form of cholecalciferol, has the ability to slow the 
decline of residual beta cell function.  Furthermore, it appears that supplementation with 
vitamin D is safe and could provide immunity benefits that have yet to be proven.   
 
Keywords:  Type 1 diabetes mellitus, vitamin D, beta cell function 
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The Effect of Vitamin D Supplementation on Preserving Pancreatic Beta Cell 
Function in Patients with Newly Diagnosed Type 1 Diabetes 
 
BACKGROUND 
 
 
 Diabetes affects 25.8 million people, approximately 8.3% of the United States 
(US) population. It is the seventh leading cause of death in the US. It is estimated that the 
total yearly cost of diabetes in the US is $174 billion dollars. Diabetes is the leading 
cause of kidney failure, non-traumatic lower limb amputations and new cases of 
blindness, along with a major cause of heart disease and stroke in adults in the US.1  Type 
One Diabetes (T1D) accounts for approximately 5-10% of all diagnosed cases of diabetes 
and the incidence is increasing.2 T1D is an autoimmune disorder in which the body’s own 
immune system mistakenly destroys the beta cells in the pancreas, the only cells in the 
body that produce insulin. A diagnosis of T1D comes with a lifetime requirement to 
inject exogenous insulin.1 Beta cell destruction occurs during and after clinical disease 
presentation and is thought to be due to a combination of genetic and environmental 
factors, including but not limited to viruses, environmental toxins or foods.2  Extensive 
research has been conducted to search for a cure, without success at this time.3 Instead, 
focus has turned to prevention. Primary prevention studies have taken place in genetically 
at risk children with attempts to avert the autoimmune destruction. Secondary 
intervention studies have been attempted in individuals with presence of autoimmune 
antibodies, but normal insulin secretion as assessed by blood sugar values. Tertiary 
intervention involves patients that already have clinical evidence of T1D and attempts to 
preserve their residual beta cell function. 4 A potential link between vitamin D deficiency 
and T1D has been explored. A birth-cohort study showed that vitamin D supplementation 
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in the first year of life reduced the risk of developing T1D.5 A prospective cross-sectional 
study showed that frequency of vitamin D deficiency in children with T1D is substantial.6 
Focus more recently has shifted to tertiary intervention and the use of vitamin D as an 
immunomodulator to preserve beta cell function in patients with clinically evident T1D.3 
Can adjunctive treatment with vitamin D in patients with newly diagnosed T1D preserve 
pancreatic beta cell function? 
 
METHODS 
 
 An exhaustive search of medical literature was conducted using Medline-OVID, 
CINAHL, EBMR Multifile and Web of Science using the keywords: vitamin D, type 1 
diabetes mellitus, and beta cell function. The bibliographies of these articles were 
extensively scanned for relevant articles. Inclusion criteria included recent diagnosis of 
T1D (less than six months), patients positive for islet autoantibodies (anti-glutamic acid 
decarboxylase 65 (GAD) or anti IA-2), and any form of vitamin D supplementation 
(calcitriol, cholecalciferol, etc). Exclusion criteria included patients with latent 
autoimmune diabetes (LADA), comparison to treatment other than placebo, and animal 
studies. Relevant articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE).7  
RESULTS 
 Preliminary searches yielded 19 articles for review. However after screening with 
established inclusion and exclusion criteria three articles remained.8,9,10  All three were 
randomized controlled trials (see table I).  Furthermore, a search on the NIH clinical trials 
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site reveals there are no active studies regarding vitamin D supplementation to preserve 
pancreatic beta cell function in patients with newly diagnosed T1D.  
 
Walter et al Study 
 
 This randomized, double blinded, placebo controlled trial8 was a two part study. 
Part one was a safety assessment of 0.25 microgram doses of 1alpha,25-
Dihydroxyvitamin D3 (1,25(OH)2D3), and part two investigated supplementation of 
1,25(OH)2D3 versus placebo in patients with newly diagnosed T1D and compared 
residual beta cell function. Twenty-five patients were enrolled in part one of the study 
from hospitals and outpatient clinics in Bavaria, Germany between November 2000 and 
2006. Twenty-one completed the study, with a 16% loss to follow up. Patients received 
0.25 micrograms 1,25(OH)2D3 daily at breakfast for nine months and were followed for 
an additional 18 months.  Primary outcomes of safety measured were plasma levels of 
calcium, phosphate, alkaline phosphatase and creatinine, urinary calcium excretion and 
kidney ultrasound. Part two of the study enrolled 40 patients and 38 patients completed 
the study, with a 5% loss to follow up.  Twenty-two patients were randomized to receive 
0.25 micrograms 1,25(OH)2D3 daily for nine months, and 18 received placebo. 
Randomization was performed by an independent pharmacy where they coded the 
medication before sending it to the Diabetes Research Institute. Primary outcome 
evaluated was the area under the curve (AUC) for stimulated C peptide release 0-120 
minutes after a mixed meal tolerance test (MMTT) comprised of Boost High Protein 
360mL collected at baseline, month 9 and month 18.  Secondary outcomes evaluated 
included: peak C peptide level after MMTT at eighteen months, daily insulin requirement 
and Glycated Hemoglobin level (HbA1C).8 
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 All patients were similar between part one and part two of the study, including 
treatment and placebo patients. Eligibility criteria included: age 18-39 years old (part 
one: median 31.2 +/- 7.3 years, part two: treatment-median 31.4 +/- 6.8 years, placebo-
median 24.0 +/- 6 years), duration of treatment with insulin less than two months (part 
two: treatment-median 35.0 days, placebo-median 40.0 days), and had a positive result on 
test for islet autoantibodies (anti-GAD antibodies or anti-IA-2 antibodies), normal values 
for plasma calcium, phosphate, alkaline phosphatase and creatinine and were compliant 
with an adequate insulin treatment regime. Exclusion criteria included: disorders in 
calcium metabolism, kidney disease, malignancy, arterial hypertension, pregnant or 
lactating women and women of child-birthing age that weren’t performing an effective 
contraception technique.8 
 All three groups (part one and treatment and placebo in part two) were 
statistically evaluated for safety efficacy. Plasma levels of calcium, alkaline phosphatase, 
phosphate and creatinine  and 24-hour urine excretion of calcium were not significantly 
different in any patients, those treated with 1,25(OH)2D3 or placebo (see table II). 
Adverse events were reported in 10% of patients and included upper respiratory tract 
infection and rhinitis but were evenly dispersed in both treatment and placebo groups and 
likely not secondary to 1,25(OH)2D3  supplementation.8 
 In part two of the study, the primary outcome measured was AUC C-peptide, 
which was decreased about 40% in both the treatment and placebo group (treatment-
baseline 90.8 +/- 30.3, month 18 58.4 +/- 47.7, placebo- baseline 98.1 +/- 33.0, month 18 
58.0 +/-33.7).  Secondary outcomes measured included: peak C peptide after MMTT, 
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daily insulin dose and HbA1C. Mean results were not significantly different in treatment 
versus placebo for any of the secondary outcomes (see table III).8 
 Overall, Walter et al8 proved that supplementation with 0.25 micrograms 
1,25(OH)2D3 is safe, but does not provide significant reduction in loss of pancreatic beta 
cell function, as assessed by production of stimulated C-peptide.8 
 
 
Bizzarri et al Study 
 
 This randomized, double blinded, placebo controlled trial9 compared the effects of 
calcitriol (the active from of vitamin D 1,25-dihydroxyvitamin D3) versus placebo in 
patients with newly diagnosed T1D and residual pancreatic beta cell function. Thirty-four 
subjects were enrolled and 27 completed the trial, with a 20% loss to follow up. 
Eligibility criteria included: diagnosis according to American Diabetes Association 
(ADA), age 18-35 years old (median 18 years old), duration of insulin therapy less than 
three months and baseline C peptide levels greater than 0.25 nmol/l.9 
 Fifteen patients were randomized to receive 0.25 micrograms calcitriol and 12 
were randomized to receive placebo.  At baseline,16 of 34 subjects had clinical evidence 
of vitamin D deficiency, and at study completion at 24 months vitamin D levels were 
slightly increased in calcitirol group (+3.9%) and slightly decreased in placebo group (-
8.0%). Primary outcome measured was AUC0-120 minutes after Boost High-Protein 
standardized liquid meal and was not significantly different between treatment and 
placebo groups at baseline or after twelve months (treatment- baseline 69.9 +/- 24.8, 
month 12 49.7 +/- 30.4, placebo- baseline 72.5 +/- 37.7, month 12 56.2 +/- 39.7). A 
secondary outcome measured was mean rate of decline in fasting C peptide (month 12- 
treatment 17.7%, placebo 28.4%, month 24- treatment 44.4%, placebo 42.5%). Of note, 
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vitamin D deficiency at diagnosis was not associated with decreased residual beta cell 
function at twenty- four months (C-peptide levels of vitamin D deficient patients- 0.19 
+/- 0.09, C peptide levels of non-vitamin D deficient patients- 0.22 +/- 0.16).9 
 Overall, this study was a designed as a second trial with calcitriol, following up 
the Walter et al8 study and was designed to use patients that were younger at diagnosis 
with a defined level of basal C- peptide at baseline, and also to assess baseline vitamin D 
status and association with residual beta cell function. It was found that serum vitamin D 
levels were only modestly altered by supplementation, and that calcitriol did not provide 
preservation of residual beta cell function in patients with clinically evident T1D. Also, 
calcium and phosphate levels were within normal limits for the duration of the study and 
no adverse events were reports in treatment or placebo groups. This study was limited by 
a small sample size, although statistical analyses were performed prior to study onset and 
it was determined that an adequate sample size was 26.9  
 
Gabbay et al Study 
 This randomized, double blinded, placebo controlled trial10 investigated the 
effects of cholecalciferol supplementation versus placebo in patients with newly 
diagnosed T1D and effect on residual beta cell function. Thirty-eight patients began the 
study at the Diabetes Center of Sao Paulo Federal University in Brazil, and 35 patients 
completed the follow-up (a 7% loss). Eligibility criteria included: age between 7 and 30 
years (treatment 13.5 +/- 5.1, placebo 12.5 +/- 4.8), length of time since first insulin 
injection (treatment 2.2 +/- 1.2 months, placebo 2.7 +/- 1.7 months), positive test for islet 
cell autoantibodies (anti GAD or anti protein tyrosine phosphatase) and fasting or 2-hour 
post-prandial stimulated serum C-peptide greater than 0.6 ng/mL. Exclusion criteria 
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included: severe systemic disease and disorders in calcium metabolism. Seventeen 
patients were randomized to receive 2000IU cholecalciferol daily and 18 patients 
received placebo, with randomization performed by a pharmacist and the pills were 
produced and concealed in an independent pharmacy. Patients were similar in regards to 
baseline characteristics, with the exception of differences in HbA1C (see table III).10    
 Primary outcome measured was cumulative incidence of stimulated C peptide to 
an undetectable level at 18 months.  C peptide was stimulated with a MMTT (mixed meal 
tolerance test) that was 6mL/kg of body weight performed between seven and ten in the 
morning after an overnight fast, and patients received no insulin for at least six hours 
prior to assessment. Overall, patients being treated with cholecalciferol were less likely to 
have an undetectable C peptide level, and had improved residual beta cell function versus 
placebo (undetectable C-peptide level, treatment group-6.2%, placebo group-37.5%, RR- 
16.5%, RRR- 83.5%, ARR- 31.3%, NNT-4). A number of secondary outcomes were 
assessed at baseline, and months 6, 12 and 18 without significant differences appreciated 
between treatment and placebo groups (see table IV).10 
 There were a number of surrogate outcomes assessed at baseline, and month 6, 12 
and 18 as well.  They included inflammatory markers and immune cells: interleukin 
twelve (IL-12), Tumor Necrosis Factor (TNF), Chemokine IL-10, IL-10, Chemokine 
Ligand Two (CCL2) and regulatory T cells. There was an increased amount of CCL2 
(baseline:treatment-192.3 +/- 92.0, placebo-168.5 +/- 87.8, month 18:treatment- 221.9 +/-
257.2, placebo-136.6 +/- 69.1) and regulatory T cells(baseline:treatment-3.34 +/-1.8, 
placebo-2.78+/-1.7, month 18:treatment-3.75+/-1.6, placebo-3.20+/-1.5) in the treatment 
group.10 
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 Overall results show that the primary outcome of residual beta cell function as a 
measure of stimulated C-peptide release favored the group treated with 2000IU 
cholecalciferol. Also, the increased level of CCL2 in the treatment group may work in an 
anti-inflammatory fashion and, in conjunction with TNF, prevent autoimmune 
destruction of beta cells. One limitation of this study was the difference in HbA1C at 
baseline of the treatment group (9.25% +/-2.17%) versus placebo (7.73% +/-2.16%).  
However HbA1C became very similar by the first follow up at month six.10 
DISCUSSION 
Vitamin D is an inexpensive, easily accessible supplement with many proposed 
health benefits.  The question remains whether one of these benefits includes preservation 
of pancreatic beta cell function in patients with newly diagnosed T1D. Both Walter et al8 
and Bizzarri et al9 showed little to no effect of vitamin D on patient important outcomes 
including daily insulin requirement and HbA1c levels. However, the safety assessment in 
Walter et al8 showed no difference in minor adverse events between treatment and 
placebo, and no adverse events that could be attributed to the medication in either group. 
All three studies8,9,10 primarily assessed capability of pancreatic beta cells to release C 
peptide. Steffes et al11 showed that beta cell function as a measure of stimulated C peptide 
release was a good prognostic indicator for patients with T1D. This included reducing 
incidences of retinopathy and nephropathy in patients with higher, and more sustained 
levels of C peptide (and insulin) secretion.11 Gabbay et al10 also assessed many other 
surrogate outcomes including inflammatory markers and plasma levels of specific auto-
immune cells. New research in T1D targets immunotherapy to preserve beta cell 
function. Keymeulen et al12 found that short term treatment with CD3 antibody preserved 
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residual beta cell function for up to 18 months in T1D.  However, every patient in the 
study experienced adverse events including: fever, headache, viral syndrome, arthralgia 
and gastrointestinal symptoms.12 Pescovitz et al13 conducted a study comparing 
Rituximab, an anti CD20 monoclonal antibody versus placebo in preserving beta cell 
function. Rituximab was found superior to placebo in preserving beta cell function in 
T1D for one year, however it had significantly more side effects than placebo (57 patients 
with 392 reported adverse events, placebo 30 people with 148 reported adverse events).13   
Gabbay et al10 was the only study to show that vitamin D supplementation, 
specifically in the form of cholecalciferol, was able to preserve pancreatic beta cell 
function in patients with newly diagnosed T1D.  This outcome was assessed based on 
progression of C peptide to an undetectable level at month 18.  Results showed that 
37.5% of patients in the placebo group had non-existent beta cell function as a function of 
C peptide release, while only 6.2% of patients in the treatment group had such a decline 
in their beta cell function.10 Based on the finding in the Steffes et al11 study it can be 
assumed that these results would directly correlate with patient important outcomes, 
including, but not limited to, decreasing daily insulin requirements, improving HbA1C 
levels and preventing future systemic complications. There are many possible 
explanations for the remarkable results supporting treatment in Gabbay et al10 as 
compared to the other two studies.8,9 Patients were younger overall in the Gabbay et al10 
study and also had an higher level of baseline beta cell function as measured by a higher 
level of fasting or stimulated C peptide than either of the other two studies.8,9 Also, in the 
first two studies8,9 the active form of vitamin D was used (1,25(OH)2D3 as opposed to 25-
hydroxyvitamin D3 in the Gabbay et al10 study. 
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Further data was extrapolated from Gabbay et al10 including an increase in Il-10, 
CCL-2, and regulatory T cells in the patients treated with cholecalciferol. According to 
Batagglia et al14 in an animal study on non-obese diabetic mice, rapamycin (an 
immunosuppressant drug) plus IL-10 protected mice from developing diabetes and 
induced long-term tolerance.14 It has also been proposed that auto-immune diseases, 
including the beta cell destruction in T1D, is induced by dysfunction of immune cells.  A 
decreased amount or dysfunctional population of regulatory T cells contributes to the 
development of T1D along with decreased levels of CCL2 that tend toward anti-
inflammatory effects.15 It can be inferred then that the increased levels of IL-10, CCL2 
and regulatory T cells could work together to prevent autoimmune destruction of 
pancreatic beta cells.10 Future research should be conducted to confirm the immune-
protective capabilities of cholecalciferol on pancreatic beta cells and rule out a chance 
outcome from this study. Research should also explore the implications of these altered 
levels of cytokines, chemokines and regulatory T cells and their impact on T1D progress 
and patient important outcomes.  
 All three studies8,9,10 are randomized control trials so they start at a high level of 
validity, but each study has significant risks to overall quality. Regarding methodology, 
all three studies8,9,10 were adequate as they each were double blinded with allocation 
concealment and none of the studies had to be stopped early.  However, Walter et al8 had 
a 16% loss to follow up and Bizzarri et al9 had a 20% loss to follow up. Regarding 
prognostic factors, Gabbay et al10 had significant differences between baseline HbA1c of 
treatment versus placebo group, however it would have appeared to be an advantage to 
the placebo group as the levels were higher in the treatment group. Regarding directness 
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of evidence, all three studies8,9,10 were highly reliant upon surrogate outcomes, primarily 
C-peptide.  The assumption had to be made that C-peptide is a good measure of 
pancreatic beta cell function, which is a good indicator of overall T1D prognosis. Also, 
Gabbay et al10 was heavily based on surrogate outcomes including levels of pro-
inflammatory and anti-inflammatory cytokines, chemokines and regulatory T cells and an 
inference must be made that these surrogate outcomes would have an impact on patient 
important outcomes. Finally, regarding precision, all three studies8,9,10 were limited by 
small sample sizes. Walter et al8 had 65 patients between part one and part two, Bizzarii 
et al9 had 34 subjects and Gabbay et al10 had 38 patients.  None of the studies8,9,10 were 
downgraded for publication bias (See Table I).  Therefore, the overall quality of evidence 
is low; however, with the safety profile of vitamin D, supplementation carries a low risk 
of harm.  
CONCLUSION 
 T1D is a chronic disease that requires daily monitoring and can lead to serious, 
systemic complications.  Extensive research has been completed exploring the etiology of 
T1D, searching for a cure and trying to halt disease progression. It appears that vitamin D 
deficiency, either in utero or during the first year of life, can increase likelihood of 
developing T1D.  Furthermore, it appears that T1D disease progression can be altered by 
immunomodulating medications, many of which have serious adverse side effects. 
Recent research on vitamin D has shown possible immune-protective capabilities.   
Overall, there isn’t compelling evidence to show that vitamin D supplementation can 
preserve pancreatic beta cell function in patients with newly diagnosed T1D. However, it 
appears that there is modest evidence to show that vitamin D in the form of 
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cholecalciferol has the ability to slow the decline of residual beta cell function.  
Furthermore, it appears that supplementation with vitamin D is safe and could provide 
additional immune-protective benefits that have yet to be proven.   
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Table I: Characteristics of Reviewed Studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a- 16% loss to follow up8 
b- small sample size, 65 patients8 
c- 20% loss to follow up9 
d- small sample size, 27 patients9 
e- strong use of surrogate outcomes including levels of proinflammatory and anti-inflammatory cytokines, chemokines and regulatory T cells10 
f- small sample size, 35 patients10 
 
 
 
 
 
 
 
 
 
Quality Assessment  
Importance  Downgrade Criteria 
Quality 
Study Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Outcome Assessed: Beta Cell Preservation   
Walter et 
al8 
RCT 
Serious 
Limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely 
Low Important 
Bizzarri 
et al9 
RCT 
Serious  
Limitationsc 
No serious 
indirectness 
Serious 
imprecisiond 
No serious 
inconsistencies 
No bias 
likely 
Low Important 
Gabbay 
et al10 
RCT 
No serious 
limitations 
Serious 
indirectnesse 
Serious 
Imprecisionf 
No serious 
inconsistencies 
No bias 
likely 
Low Important 
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Table II- Baseline Characteristics (Walter et al study) 
Table II: Baseline Characteristics (Walter et al Study) 
 
Calcium 
(mmol/L) 
Alkaline 
Phosphatase 
(IU/mL) 
Phosphate 
(mmol/L) 
Creatinine 
(mg/dL) 
24-h 
calcium 
urine 
excretion 
(mmol/24h) 
AUC C-peptide 
(nmol/L x 120 min 
Fasting C- 
Peptide 
(nmol/L 
Peak C- 
peptide 
(nmol/L) 
A1C (%) Daily 
Insulin 
Dose 
(IU/day) 
Treatment 
Group 
2.4 +/- 
0.1 
67 +/- 19 1.2 +/- 0.2 0.8 +/- 0.1 6.3 +/- 3.2 90.8 +/- 30.3 0.33 +/- 0.12 1.00 +/- 
0.37 
8.4 +/- 
2.1 
24.9 
+/- 
12.6 
Placebo 
Group 
2.5 +/- 
0.1 
65 +/- 26 1.2 +/- 0.2 0.8 +/- 0.1 6.1 +/- 3.2 98.1 +/- 33.0 0.34 +/- 0.13 1.10 +/- 
0.36 
8.3 +/- 
1.6 
24.6 
+/- 8.9  
 
Table II- Outcomes Measured-Month 18 (Walter et al 
study) 
 
Table III: Outcomes Measured- Month 18 (Walter et al Study) 
 
AUC C-peptide 
(nmol/L x 120 min) 
Fasting C- peptide 
(nmol/L) 
Peak C- peptide 
(nmol/L) 
A1C (%) Daily Insulin Dose 
(IU/day) 
Treatment  
Group 
58.4 +/- 47.7 0.19 +/- 0.18 0.66 +/- 0.52 6.1 +/-  0.6 35.6 +/- 19.2 
Placebo  
Group 
58.0 +/- 33.7 0.22 +/- 0.15 0.63 +/- 0.34 6.3 +/- 0.8 34.9 +/- 18.1 
 
Table II-Baseline Characteristics and Outcomes 
Measured Month 18  (Gabbay et al study) 
 
 
Table IV: Gabbay et al Study 
Baseline Characteristics  
 
Fasting C- peptide 
(ng/mL) 
Stimulated C-peptide 
(ng/mL) 
A1C 
(%) 
Daily Insulin Dose 
(U/kg/d) 
Body Mass Index 
Treatment  
Group 
0.65 +/- 0.45 1.55 +/- 0.91 9.25 +/- 2.17 0.52 +/- 0.19 18.5 +/- 3..0 
Placebo 
Group 
0.92 +/- 0.83 1.83 +/- 1.03 7.73 +/- 2.16 0.43 +/- 0.19 18.5 +/- 2.5 
Outcomes Measured- Month 18 
Treatment  
Group 
0.45 +/- 0.34 1.0 +/- 1.03 8.29 +/- 2.06 0.81 +/- 0.37 19.5 +/- 2.8 
Placebo 
Group 
0.43 +/- 0.49 0.96 +/- 1.08 8.91 +/- 2.71 0.80 +/- 0.27 20.5 +/- 4.2 
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